Research alert: GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists — the class of drugs behind Ozempic, Wegovy and Mounjaro, for example —…